Over the past five years, the BSE healthcare index has surged by 80%, with 62 out of 98 listed stocks delivering positive returns. Among them, six stocks have particularly stood out, rewarding investors with remarkable gains of up to 2000%.
Leading the pack is Gujarat Themis Biosyn, showcasing exceptional growth in the last half-decade span. During this time, the company's shares have soared by an impressive 2030%, skyrocketing from ₹37.65 apiece to ₹802. Notably, the stock has consistently delivered 50% returns annually for the past four years. In CY18, it posted a return of 91%, followed by a phenomenal 324% in the subsequent year. The trend continued with splendid returns of 91% and 62% in CY21 and CY22, respectively.
Jagsonpal Pharmaceuticals closely follows, demonstrating impressive performance with a stellar rise of 1583%. Impressively, the company's shares have delivered over 100% returns in the last three years, rising by 176%, 152.64%, and 106.30% in CY20, CY21, and CY22, respectively.
Jagsonpal Pharmaceuticals Limited is a Delhi-based pharmaceutical company. The company has a robust portfolio of drugs focusing on the Gynecology and Orthopedic segments. For the June-ending quarter, the company reported a strong set of numbers, with its net profit growing by 159% YoY to ₹7.48 crore.
The third standout gainer is J B Chemicals & Pharmaceuticals. The company shares have grown steadily over the past five years, delivering a substantial return of 742%.
The company is one of the fastest-growing pharmaceutical companies in India and a leading player in the hypertension segment. Besides its strong India presence, which accounts for the majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has six brands among the top 300 IPM brands in the country.
J B Pharma recorded revenue growth of 14% to ₹896 crore in Q1FY24. The domestic formulations business stood at ₹489 crore, recording a growth of 17%. The revenue from international business crossed ₹400 crore in Q1 for the first time in a quarter. The company reported a 35% YoY growth in net profit of ₹142 crore in Q1.
| Scrip Name | Five-year returns |
| Gujarat Themis Biosyn | 2,030% |
| Jagsonpal Pharmaceuticals | 1,583% |
| J B Chemicals & Pharmaceuticals | 742% |
| Poly Medicure | 552% |
| Neuland Laboratories | 508% |
Similarly, Poly Medicure has secured its place among the top wealth creators. The company shares, which were trading at ₹212 apiece five years ago, have spiked to ₹1,382, reflecting a surge of 552%.
Poly Medicure is a medical device manufacturing company based in India. The company specializes in the production of medical consumables and devices for healthcare providers worldwide. The company offers a wide range of products, including intravenous (IV) catheters, infusion sets, blood bags, disposable syringes, and other medical accessories.
The company reported its highest-ever quarterly consolidated net profit of ₹63 crore in Q1FY24. It had achieved a net profit of ₹27 crore in the same period last year and ₹59 crore in the preceding March quarter.
From a trading price of ₹685 apiece five years ago, shares of Neuland Laboratories have risen by 508% to trade at the current market price of ₹4,167. The company is a pharmaceutical manufacturer that provides active pharmaceutical ingredients (APIs), complex intermediates, and custom manufacturing solutions services to customers located in around 80 countries.
The company's total income for Q1FY24 stands at ₹365 crore, up by 64.7% YoY, led by growth in Specialty and CMS segments. The operating profit during the quarter reached ₹99.3 crore, experiencing an impressive YoY growth of 242.5%. Notably, the EBITDA margin for Q1FY24 stood at 27.2%, marking a significant increase of 1410 basis points (bps) YoY.
The company's profit after tax for Q1FY24 reached ₹62.2 crore, demonstrating a remarkable surge of 532.3% YoY.
Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of MintGenie.
